ArticleFrontiers in pharmacology2025
Cardiovascular effects of 6-nitrodopamine, adrenaline, noradrenaline, and dopamine in normotensive and hypertensive rats.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- New Insights into Cardiac Intensive Care.Reviews in cardiovascular medicine · 2026Review
- Improved Synthesis of 5-Nitrohomovanillic Acid and 6-Nitrohomovanillic Acid as Probes for Metabolism Studies of Endothelium-Derived Dopamines: Identification in Human Amniotic Fluid.Molecules (Basel, Switzerland) · 2025Article
- The identification of adenylyl cyclase modulators as potential receptors for 6-nitrodopamine in human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and their relevance in heart inotropism.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: 6-Nitrodopamine (6-ND) has been extensively investigated using in vitro protocols, especially in the cardiovascular system. Despite the established more potent positive chronotropic and inotropic effects, in comparison with the classical catecholamines, adrenaline (ADR), noradrenaline (NA) and dopamine (DA), the effects with in vivo models are not determined yet. Here, we investigated the acute effects on heart rate (HR) and mean arterial blood pressure (MABP) in normotensive and hypertensive rats by 6-ND. Methods: Adult male Wistar rats were randomly divided into two groups: one received regular filtered water and the other a chronic Nω-nitro-L-arginine methyl ester (L-NAME) treatment in the water (20mg/day/rat, 4weeks). Thereafter, the animals were anesthetized, the HR and MABP were monitored through the femoral artery, and the vein was used to administer bolus injections of 6-ND, ADR, NA and DA. Moreover, 6-ND, classical and novel catecholamines, 6-cyanodopamine (6-CYANO), 6nitroadrenaline (6-NADR), and 6-nitrodopa (6-NDOPA) were used to assess their effect on monoamine oxidase (MAO) activity. Results: All four drugs significantly increased the HR in control animals; 6-ND was more potent than the classical catecholamines and its positive chronotropic effect was abolished with the chronic L-NAME treatment. Furthermore, in a cell-free assay, 6-ND was able to partially inhibit MAO-A (<30% at 1 mM) and MAO-B (<40% at 10 μM); 6-NDOPA and 6-CYANO (1 mM) inhibited MAO-A, and MAO-B by around 40%, respectively. ADR produced MAO-A inhibition of <20%, at 100μM. Conclusions: These results clearly demonstrate that 6-ND is the most potent endogenous positive chronotropic agent yet described, and its effects are independent of MAO inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.